Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic assetSTX-1150 is designed to deliver durable therapeutic LDL-C lowering with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results